Daewoong Pharmaceutical, 53,181 Shares Net Sold by Individuals in Last 5 Days... Stock Price at 211,000 KRW (+20.23%)

Daewoong Pharmaceutical is trading at 211,000 KRW as of 1:31 PM on the 18th, up 20.23% from the previous day. The trading volume is 4,538,891 shares, which is 70.54% of the previous day's volume. Daewoong Pharmaceutical is known as a leading pharmaceutical company manufacturing and selling drugs such as Urusa and Albis.

On December 17, researcher Lee Hye-rin from KTB Investment & Securities stated, "After the US market closed early morning, the ITC final ruling was announced. A 21-month import ban order was issued. The market had already reflected the worst-case scenario of the ITC lawsuit, so this is considered a positive issue. The preliminary ruling of a 10-year import ban was the worst case, and thus the value of Nabota’s export business was reflected as zero when calculating Daewoong Pharmaceutical’s target price. If the final ruling does not overturn the result, the punitive damages portion from Evolus had to be considered, and this risk was factored into the target price." He set Daewoong Pharmaceutical’s target price at 130,000 KRW.

Over the past five days, individual investors have net sold 53,181 shares of Daewoong Pharmaceutical, while foreigners and institutions have net bought 11,757 shares and 46,187 shares, respectively.

※ Source: AI Investment Assistant AI Rassiro

※ This article was generated in real-time by an automatic article generation algorithm jointly developed by Asia Economy and financial AI specialist Thinkpool.

This content was produced with the assistance of AI translation services.